Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EIDX

Eidos Therapeutics (EIDX) Stock Price, News & Analysis

Eidos Therapeutics logo

About Eidos Therapeutics Stock (NASDAQ:EIDX)

Advanced Chart

Key Stats

Today's Range
$122.21
$122.21
50-Day Range
$120.98
$128.51
52-Week Range
$28.39
$132.54
Volume
N/A
Average Volume
128,113 shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Receive EIDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eidos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EIDX Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
The Anglo File: Game Over for Board Lapses at Eidos
See More Headlines

EIDX Stock Analysis - Frequently Asked Questions

Eidos Therapeutics, Inc. (NASDAQ:EIDX) issued its earnings results on Thursday, October, 29th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.71) by $0.08. The business earned $0.13 million during the quarter.

Eidos Therapeutics (EIDX) raised $101 million in an initial public offering (IPO) on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eidos Therapeutics investors own include Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Exelixis (EXEL), NVIDIA (NVDA), Micron Technology (MU), Axsome Therapeutics (AXSM) and Occidental Petroleum (OXY).

Company Calendar

Last Earnings
10/29/2020
Today
4/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EIDX
CIK
N/A
Fax
N/A
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,830,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$26.69 million
Price / Cash Flow
N/A
Book Value
$4.57 per share
Price / Book
26.74

Miscellaneous

Free Float
N/A
Market Cap
$4.75 billion
Optionable
Not Optionable
Beta
-0.16
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:EIDX) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners